For over 50 years, Parkinson’s disease has challenged scientists with its progressive and irreversible damage to the brain.
Most patients rely on medications that lose their effect over time. But now, a small group of researchers may have taken a major step forward.
In a recent phase 1 clinical trial, scientists from Memorial Sloan Kettering Cancer Center transplanted lab-grown dopamine-producing neurons directly into the brains of 12 patients.
This replace the exact type of brain cell that Parkinson’s destroys.
These neurons, made from embryonic stem cells, were designed to release dopamine – a key chemical responsible for movement control.
In Parkinson’s disease, dopamine levels drop dramatically, leading to tremors, stiffness, and mobility issues.
From the lab to the brain
Developed over two decades by Dr. Lorenz Studer and Dr. Viviane Tabar, the cell product, called bemdaneprocel, was frozen and ready to use when patients were selected.
Using advanced MRI-guided surgery, the team implanted the cells into a specific brain region – precisely where they were most needed.
Patients then received a year of immunosuppressive medication to prevent rejection.
No serious side effects were reported. Even more striking, several patients showed signs of symptom stabilization or improvement.
One of the most promising outcomes came from those who received a higher dose: their daily “ON” time – hours without debilitating symptoms – increased by nearly three hours.
That’s three more hours a day where life feels normal.
What’s next for the therapy?
Despite these exciting results, researchers urge caution. The trial involved just 12 patients and lacked a control group.
Still, the results were convincing enough for the U.S. FDA to approve a much larger phase 3 trial set to begin in 2025.
This new study will include around 100 participants and a placebo group, which will help determine if the benefits truly come from the treatment.
If the results hold, it could mark a new era in regenerative medicine – not just for Parkinson’s, but potentially for other neurodegenerative diseases.
After decades of research, what began as a long-shot scientific dream might finally be within reach.
This article is based on information from News-medical.net.